Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines

Blood

Volumn 96, Issue 5, 2000, Pages 1933-1939

  Jonuleit, T ^a   Van Der Kuip, H ^a   Miething, C ^a   Michels, H ^a   Hallek, M ^a   Duyster, J ^a   Aulitzky, W E ^a  

^a ROBERT BOSCH HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P27;

ANIMAL CELL; ARTICLE; CELL CYCLE; CELL GROWTH; CELL SURVIVAL; CHRONIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; GENE OVEREXPRESSION; GROWTH REGULATION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0034283987     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.5.1933     Document Type: Article

References (58)

1. Identification of a Myc-dependent step during the formation of active G1 cyclin-cdk complexes
2. Activation of c-Myc uncouples DNA replication from activation of G1-cyclin-dependent kinases
3. BCR-ABL-induced oncogenesis is mediated by direct interaction wih the SH2 domain of the GRB-2 adaptor protein
4. Negative regulation of p120GAP GTPase promoting activity by p210bcr/abl: Implication for RAS-dependent Philadelphia chromosome positive cell growth
5. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene
6. Mutant forms of growth factor-binding protein-2 reverse BOR-ABL-induced transformation
7. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells
8. Dominant negative MYC blocks transformation by ABL oncogenes
9. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia
10. Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein
11. Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells
12. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation
13. In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome
14. Transformation of an interleukin 3-dependent hematopoletic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein
15. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia
16. Abl tyrosine protein kinase
17. The BCR-ABL oncogene requires both kinase activity and src-homology 2 domain to induce cytokine secretion
18. Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2
19. Bcr-Abl kinase promotes cell cycle entry of primary myeloid CML cells in the absence of growth factors
20. The Bcr-Abl tyrosime kinase activates mitogenic signalling pathways and stimulates G1-to-S phase transition in hematopoietic cells
21. Inhibitors of mammalian G1 cyclin-dependent kinases
22. G1 phase progression: Cycling on cue
23. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest
24. Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function
25. Inhibition of ras-induced proliferation and cellular transformation by p16INK4
26. Novel INK4 proteins, p19 and p18, are specific inhibitars of the cyclin D-dependent kinases CDK4 and CDK6
27. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4
28. WAF1, a potential mediator of p53 tumor suppression
29. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals
30. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21
31. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution
32. Imprinting of the gene encoding a human cyclin-dependent kinase inhibitor, p57KIP2, on chromosome 11p15
33. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases
34. p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene
35. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice
36. Interaction of the receptor tyrosine kinase p145c-kit with the p210bcr/abl kinase in myeloid cells
37. Isolation of temperature-sensitive tyrosine kinase mutants of v-abl oncogene by screening with antibodies for phosphotyrosine
38. The SH2-containing adapter protein GRB10 interacts with bcr-abl
39. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
40. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
41. Ras activity late in G1 phase required for p27(kip1) downregulation, passage through the restriction point, and entry into S phase in growth factor-stimulated NIH 3T3 fibroblasts
42. Expression of bcr-abl abrogates factor-dependent growth of human hematopoietic M07E cells by an autocrine mechanism
43. Transforming growth factor-beta relieves stem cell factor-induced proliferation of myelogenous leukemia cells through inhibition of binding of the transcription factor NF-jun
44. TGF beta inhibition of Cdk4 synthesis is linked to cell cycle arrest
45. Differential regulation of p27 and cyclin D1 by TGF-beta and EGF in C3H 10T1/2 mouse fibroblasts
46. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest
47. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
48. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27
49. Oncogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degardation of target proteins through a Ras-independent pathway
50. The von hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal
51. Inhibition of transcription elongation by the VHL tumor suppressor protein
52. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C
53. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins
54. cul-1 is required for cell cycle exit in C. elegans and identifies a novel gene family
55. Phosphatidylinositol 3' kinase: One of the effectors of Ras
56. Deficient cell cycle control in myeloid cells of patients with newly diagnosed chronic myeloid leukemia
57. Unregulated proliferation of primitive chronic myeloid leukemia progenitors in the presence of normal marrow adherent cells
58. Clonal evolution in a myeloid cell line transformed to interleukin-3 independent growth by retroviral transduction and expression of p210bcr/abl